These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 39091916)

  • 21. BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma.
    Xu D; Gao Y; Yang H; Spils M; Marti TM; Losmanová T; Su M; Wang W; Zhou Q; Dorn P; Shu Y; Peng RW
    JTO Clin Res Rep; 2024 May; 5(5):100672. PubMed ID: 38715965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
    Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
    Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis.
    Yang L; Song X; Zeng W; Zheng Z; Lin W
    Orphanet J Rare Dis; 2023 Oct; 18(1):326. PubMed ID: 37845696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges.
    Parikh K; Hendriks LEL; Bironzo P; Remon J
    Cancer Treat Rev; 2021 Sep; 99():102250. PubMed ID: 34174669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
    Quispel-Janssen J; van der Noort V; de Vries JF; Zimmerman M; Lalezari F; Thunnissen E; Monkhorst K; Schouten R; Schunselaar L; Disselhorst M; Klomp H; Hartemink K; Burgers S; Buikhuisen W; Baas P
    J Thorac Oncol; 2018 Oct; 13(10):1569-1576. PubMed ID: 29908324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
    Bronte G; Delmonte A; Burgio MA; Verlicchi A; Puccetti M; Bravaccini S; Cravero P; Tumedei MM; Diano D; Rossi G; Ulivi P; Martinelli G; Crinò L
    Lung Cancer; 2020 Apr; 142():47-50. PubMed ID: 32088605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Response of Primary Malignant Pericardial Mesothelioma with Peritoneal Dissemination to Nivolumab.
    Fujiwara S; Kano Y; Maejima Y; Fujioka T; Tamura K; Kirimura S; Miyake S; Okamoto R
    Intern Med; 2024 Feb; 63(4):513-519. PubMed ID: 37380459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
    Carbone DP; Ciuleanu TE; Schenker M; Cobo M; Bordenave S; Juan-Vidal O; Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Felip E; Zurawski B; Alexandru A; Paz-Ares L; Lu S; John T; Zhang X; Mahmood J; Hu N; De T; Santi I; Penrod JR; Yuan Y; Lee A; Reck M
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38346853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
    Dumoulin DW; Douma LH; Hofman MM; van der Noort V; Cornelissen R; de Gooijer CJ; Burgers JA; Aerts JGJV
    Lung Cancer; 2024 Jan; 187():107440. PubMed ID: 38104353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights.
    López-Castro R; Fuentes-Martín Á; Medina Del Valle A; García Peña T; Soro García J; López González L; Cilleruelo Ramos Á
    Open Respir Arch; 2024; 6(3):100323. PubMed ID: 38660145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-Analysis.
    Tsai YC; Chen HL; Lee TH; Chang HM; Wu KL; Chuang CH; Chang YC; Tu YK; Hung JY; Yang CJ; Chong IW
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes.
    Jones RG; Karthik F; Dugar A; Kanagarajan K; Desai K; Bhandari M
    Am J Case Rep; 2018 Jul; 19():783-789. PubMed ID: 29970876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
    Paz-Ares LG; Ramalingam SS; Ciuleanu TE; Lee JS; Urban L; Caro RB; Park K; Sakai H; Ohe Y; Nishio M; Audigier-Valette C; Burgers JA; Pluzanski A; Sangha R; Gallardo C; Takeda M; Linardou H; Lupinacci L; Lee KH; Caserta C; Provencio M; Carcereny E; Otterson GA; Schenker M; Zurawski B; Alexandru A; Vergnenegre A; Raimbourg J; Feeney K; Kim SW; Borghaei H; O'Byrne KJ; Hellmann MD; Memaj A; Nathan FE; Bushong J; Tran P; Brahmer JR; Reck M
    J Thorac Oncol; 2022 Feb; 17(2):289-308. PubMed ID: 34648948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in
    Oehl K; Vrugt B; Wagner U; Kirschner MB; Meerang M; Weder W; Felley-Bosco E; Wollscheid B; Bankov K; Demes MC; Opitz I; Wild PJ
    Clin Cancer Res; 2021 Apr; 27(8):2277-2291. PubMed ID: 33547197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in Immunotherapy of Malignant Pleural Mesothelioma.
    Liao D; Yu Y; Mei Q; Wang Z; Li X; Jia Y; Kong F
    Onco Targets Ther; 2021; 14():4477-4484. PubMed ID: 34429612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
    Nishio M; Ohe Y; Ikeda S; Yokoyama T; Hayashi H; Fukuhara T; Sato Y; Tanaka H; Hotta K; Sugawara S; Daga H; Okamoto I; Kasahara K; Naito T; Li L; Gupta RG; Bushong J; Mizutani H
    Int J Clin Oncol; 2023 Oct; 28(10):1354-1368. PubMed ID: 37548831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis.
    Cantini L; Pecci F; Murrone A; Tomasetti M; Copparoni C; Fiordoliva I; Morgese F; Rinaldi S; Mazzanti P; Rubini C; Cimadamore A; Barbisan F; Giampieri R; Scarpelli M; Santarelli L; Berardi R
    Lung Cancer; 2020 Aug; 146():318-326. PubMed ID: 32622302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nose in malignant mesothelioma-Prediction of response to immune checkpoint inhibitor treatment.
    Disselhorst MJ; de Vries R; Quispel-Janssen J; Wolf-Lansdorf M; Sterk PJ; Baas P
    Eur J Cancer; 2021 Jul; 152():60-67. PubMed ID: 34087572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.